Merck’s Iain Dukes On New BD Culture: Regional Hubs And Sourcing Innovation
This article was originally published in The Pink Sheet Daily
Since Dukes arrived six months ago as head of Merck Research Labs’ licensing and external affairs, Merck has consolidated and restructured its scattered business development functions, rolled out its regional BD hubs, and rationalized the distinction between equity investments and venture fund investments
You may also be interested in...
Pfizer’s Centers for Therapeutic Innovation program has grown in less than three years to include 24 academic partners. First drug candidate to emerge from the research model is expected to enter the clinic this year, and Pfizer’s investment in CTI has grown.
J&J’s new London innovation center has just opened and Boston, San Francisco and Shanghai sites are soon to follow. A J&J executive providing an update in NY faced questions from a somewhat skeptical audience of potential customers, revealing nuances and new information about how the centers will operate.
Merck contributes to Flagship’s latest fund, both sides promise to share ideas and expertise, but Merck gets no special rights to companies or products in Flagship’s portfolio.